The bad news? Fewer deals happened in the 1st half 2012 -- with only 59 in the last Qtr.
Worse news? Deals are also smaller -- averaging only $9.3 M per deal or back to 2007 levels. Plus back ends have shrunk in size as well.
Worst news? IPOs are non-existent. Total global VC dollars spent on biotech dropped by 43% over prior year to only $550 M in 1st half. European companies only received $48 M of that. OUCH!
In fact, biotechs raised only $2.76 billion in the second quarter, down 46.4%. For the full first half of the year, private and public biotechs raised only $7.9 billion, down 40% from the same period in 2011.
See rest of the story here in Fierce Biotech (here and here).
Posted by Bruce Lehr July 11th 2012
Considering the shaky economy, this isn't surprising; clearly, financial considerations are playing a large part in the corresponding declines of biotech funding and patent applications by startup companies. Hopefully, this trend will reverse when (if?) the economy picks up again.
http://www.generalpatent.com/blog
Posted by: patent litigation | 07/16/2012 at 12:36 PM